NeurologyLive

11/29/2025

🧠 Evolving Approaches to Seronegative NMOSD

At ECTRIMS 2025, experts presented updates to the proposed diagnostic criteria for neuromyelitis optica spectrum disorder (NMOSD)—including new considerations for double-seronegative disease.

In an interview with NeurologyLive®, Álvaro Cobo-Calvo, MD, PhD, discussed the international panel’s work examining distinctions between AQP4-positive and seronegative presentations. He noted key differences in demographics, clinical features, and biomarker profiles, raising questions about whether seronegative NMOSD should remain within the diagnostic umbrella or be separated.

Importantly, he highlighted new evidence showing:
• Targeted therapies like satralizumab and inebilizumab show strong efficacy in AQP4-positive
• These same treatments show limited relapse reduction in double-seronegative patients
• Ongoing debate remains, with consensus still needed before criteria updates are finalized

Watch the full interview to learn how evolving evidence may shape future diagnosis and therapeutic strategies: https://hubs.li/Q03VYsjX0

The neurologist at the Multiple Sclerosis Center of Catalonia talked about the challenges of defining seronegative in new diagnostic criteria for neuromyelitis optica spectrum disorder [WATCH TIME: 5 minutes]

11/29/2025

💡 New Insight: The Future of Anti-Tau Drug Development in Alzheimer Disease

As Alzheimer Awareness Month highlights the need for better detection and treatments, researchers are turning their focus to tau pathology, which more closely reflects symptom severity and disease progression.

In this new interview, Charles Bernick, MD, from the Cleveland Clinic Lou Ruvo Center for Brain Health, explores:
• Why tau has become a leading therapeutic target
• How monoclonal antibodies, antisense oligonucleotides, and small-molecule inhibitors differ
• The growing role of tau PET and plasma biomarkers in patient selection
• The biggest unanswered questions shaping the next wave of drug development

Read More: https://hubs.li/Q03VY1bq0

Charles Bernick, MD, a staff neurologist at the Cleveland Clinic Lou Ruvo Center for Brain Health, commented on the scientific rationale, therapeutic strategies, and biomarker advances driving the next wave of anti-tau drug development in Alzheimer disease.

11/28/2025

New data from the SAkuraMOON study evaluated the long-term safety and efficacy of satralizumab (Enspryng) in 166 individuals with AQP4-IgG+ neuromyelitis optica spectrum disorder (NMOSD).

Researchers reported that satralizumab used alongside immunosuppressive therapy demonstrated sustained safety and efficacy over time, supporting its role as a potential maintenance therapy option. Genentech

📄 Read more:

A recent study confirms satralizumab's long-term safety and efficacy for treating neuromyelitis optica spectrum disorder, supporting its use as a maintenance therapy.

11/28/2025

📘 New Research in Migraine Care!

A 3-year prospective, real-world cohort study published in Headache evaluated Theranica’s Nerivio remote electrical neuromodulation wearable. Findings showed sustained long-term treatment effects without evidence of tachyphylaxis, supporting the device’s durability, safety, and continued effectiveness for management. American Headache Society®

Read more 👉

A new study confirms the Nerivio REN wearable provides long-term, drug-free migraine relief without dosage increases, ensuring consistent effectiveness over 3 years.

11/28/2025

: New phase 3 PRECLUDE trial results are in!

Researchers reported that 2 dosing regimens of onabotulinumtoxinA did not significantly reduce migraine days versus placebo for patients with episodic migraine. 💊🧠 American Headache Society®

Although onabotulinumtoxinA remains an established preventive therapy for chronic migraine, these findings highlight the need for further research to better understand differences between episodic and chronic migraine—and whether certain episodic migraine subgroups may still benefit.

Read more ⬇️

Despite not meeting its primary efficacy end point for preventive treatment of episodic migraine, onabotulinumtoxinA was well tolerated and safety outcomes were consistent with prior data.

11/27/2025

🧠 New Insight into Risk After Traumatic Brain Injury

Chronic Traumatic Encephalopathy (CTE) remains diagnosable only after death—but new research from the Brain Injury Research Center at Mount Sinai offers important clarity on who is most at risk.

In a postmortem analysis of 47 brain donors, researchers led by Enna Selmanovic, PhD candidate, found that:
• CTE was relatively uncommon, even among people with prior TBI
• Nearly all CTE cases showed substantial exposure to repetitive head impacts (RHIs)—such as contact sports, military service, or interpersonal violence
• Individuals with only isolated TBIs rarely demonstrated CTE pathology
• Many with high RHI exposure still did not develop CTE, underscoring the role of genetics, biology, and vascular factors

Selmanovic also addressed major misconceptions, including the belief that concussion = CTE, or that CTE can currently be diagnosed in the living.

Read more about it here: https://hubs.li/Q03VYcgj0

Enna Selmanovic, a PhD candidate at Mount Sinai, spoke on a recently published study regarding the incidence of traumatic brain injury and the potential for long-term health issues with chronic traumatic encephalopathy.

11/27/2025

🏈 New Insight Into CTE Detection in Living Athletes

As Thanksgiving and football season collide, NeurologyLive highlights new research from NYU Langone exploring potential markers of chronic traumatic encephalopathy (CTE)—a disease still only diagnosable after death.

In a groundbreaking study, Shae Datta, MD, co-director of the NYU Concussion Center, and international collaborators examined the brain structures of former American football players. They found that longer playing careers and earlier exposure to tackle football were associated with wider and shallower sulci, which may reflect underlying tau-related cortical atrophy.

Dr. Datta discusses:
• Why identifying CTE during life is essential
• How sulcal morphology may serve as a future imaging biomarker
• Misconceptions that still challenge clinicians
• The next steps needed to advance diagnosis and protect athletes

Read about it here: https://hubs.li/Q03VY7wS0

Shae Datta, MD, co-director of the NYU Concussion Center, explained new findings regarding potential CTE diagnosis in living patients.

11/27/2025

📣 New NeuroVoices Interview: Understanding Variability in Infantile Epileptic Spasms Syndrome (IESS) Care

Infantile spasms require fast, effective treatment — but national care patterns still vary widely. In a new conversation, Dr. Christina Briscoe of Boston Children’s Hospital discusses why early recognition is critical, what drives differences in treatment across centers, and how coordinated research can help ensure every child receives timely, evidence-based care.

She highlights gaps in access, challenges after first-line therapy fails, and the pressing need for standardized pathways, especially for ketogenic diet and surgical evaluation.

Read More: https://hubs.li/Q03VXN0m0

The pediatric epileptologist at Boston Children’s Hospital discussed national variability in treating infantile epileptic spasms syndrome and the evidence gaps that continue to shape clinical decision making.

11/27/2025

This Thanksgiving, we’re grateful for the clinicians, researchers, and advocates advancing neurologic care every day. Thank you for your commitment to improving outcomes for patients and families. 🧠🦃
Wishing you a restorative and meaningful holiday.

11/26/2025

Dyne Therapeutics is pushing the boundaries of targeted delivery in DM1 and DMD. In our Q&A, Doug Kerr, MD, PhD, explains how the FORCE platform improves tissue pe*******on and why early signals in strength, myotonia, and timed function are generating enthusiasm. 💪

He also discusses the phase 1/2 ACHIEVE and DELIVER designs and what emerging data may mean for future regulatory paths.

🔖

Doug Kerr, MD, PhD, chief medical officer at Dyne Therapeutics, discusses the clinical development of DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy.

11/26/2025

New findings from the phase 3 EVOKE and EVOKE+ trials show that semaglutide, despite improving several AD-related biomarkers, did not slow disease progression in early symptomatic Alzheimer disease. 🧠

More than 3800 adults were randomized, and the therapy remained well tolerated. Novo Nordisk will discontinue the extension phase based on the overall efficacy results.
Our coverage:

Results from the EVOKE and EVOKE+ phase 3 studies reported that oral semaglutide did not significantly reduce clinical progression in patients with early symptomatic Alzheimer disease.

11/26/2025

Promising news in stroke prevention: the phase 3 OCEANIC STROKE trial has met its primary end point with asundexian, Bayer’s factor XIa inhibitor. 🧠

In over 12,300 patients with recent non-cardioembolic stroke or high-risk TIA, the therapy reduced symptomatic ischemic stroke and MRI-detected brain infarcts. Full results are expected at an upcoming scientific meeting.

Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.